Mario Filion
pharmaceutical industry
Alethia Biotherapeutics
Canada
Biography
Mario was involved in the creation of Alethia in 2002. In his current position, he oversees Alethia’s operations including research and development, pre-clinical studies, collaborations with Universities . Prior, he acted as President of the Clinical Genomics Unit at SignalGene. Prior to joining SignalGene, Mario served as Director, Biotechnology at T2C2/Bio, a leading venture capital fund in Montréal. Earlier in his career, he acted as Director, Molecular Genetics of Algène Biotechnologies. Mario holds a Ph.D. degree in molecular biology from l’Université de Montréal and was an NSERC and FRSQ post-doctoral fellow at McGill University.
Research Interest
Mario was involved in the creation of Alethia in 2002. In his current position, he oversees Alethia’s operations including research and development, pre-clinical studies, collaborations with Universities . Prior, he acted as President of the Clinical Genomics Unit at SignalGene. Prior to joining SignalGene, Mario served as Director, Biotechnology at T2C2/Bio, a leading venture capital fund in Montréal. Earlier in his career, he acted as Director, Molecular Genetics of Algène Biotechnologies. Mario holds a Ph.D. degree in molecular biology from l’Université de Montréal and was an NSERC and FRSQ post-doctoral fellow at McGill University.
